BioNTech Reports Q3 Revenue of €1.29 Billion, Narrows 2026 Guidance
BioNTech narrowed its full-year 2026 revenue guidance to €1.7 billion–€1.9 billion, raising the midpoint of its previous forecast. It also exercised a Roche/Genentech collaboration option that shifts future program R&D costs to the partner from January 1, 2027, while preserving BioNTech’s eligibility for future royalties.
BioNTech SE announced its financial results for the third quarter and first nine months of 2026, reporting third-quarter revenue of €1.29 billion. The company narrowed its full-year 2026 revenue guidance to a range of €1.7 billion to €1.9 billion, raising the midpoint of its previous forecast. Additionally, BioNTech exercised an option in its collaboration agreement with Roche/Genentech, which will shift future R&D costs for the program to the partner starting January 1, 2027, while maintaining BioNTech's eligibility for future royalties.
Management emphasized that the company remains focused on its late-stage oncology pipeline and continues to return capital to shareholders through its share repurchase program.